Effects of control interventions on Clostridium difficile infection in England: an observational study

The Lancet Infectious Diseases

Volumn 17, Issue 4, 2017, Pages 411-421

  Dingle, Kate E ^a,b,c   Didelot, Xavier ^d   Quan, T Phuong ^a,b,c   Eyre, David W ^a,b   Stoesser, Nicole ^a,b   Golubchik, Tanya ^a,b   Harding, Rosalind M ^b,c   Wilson, Daniel J ^a,b,e   Griffiths, David ^a,b   Vaughan, Alison ^a,b   Finney, John M ^a,b   Wyllie, David H ^a,b,d   Oakley, Sarah J ^f   Fawley, Warren N ^g   Freeman, Jane ^g   Morris, Kirsti ^g   Martin, Jessica ^g   Howard, Philip ^h   Gorbach, Sherwood ^i,j   Goldstein, Ellie J C ^k   Citron, Diane M ^k   Hopkins, Susan ^c,d,l   Hope, Russell ^d   Johnson, Alan P ^c,d   Wilcox, Mark H ^g   Peto, Timothy E A ^a,b,c   Walker, A Sarah ^a,b,c   Crook, Derrick W ^a,b,c   Del Ojo Elias, Carlos ^m   Crichton, Charles ^m   Kostiou, Vasiliki ^m   Giess, Adam ^m   Davies, Jim ^m   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^g LEEDS GENERAL INFIRMARY   (United Kingdom)

^h LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

ⁱ CUBIST PHARMACEUTICALS INC   (United States)

^j TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k R M ALDEN RESEARCH LABORATORY   (United States)

^l ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^m Public Health England ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE TRANSMISSION; ENGLAND; GENE SEQUENCE; GENOME ANALYSIS; GENOTYPE; HEALTH SERVICES RESEARCH; HUMAN; INCIDENCE; INFECTION CONTROL; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; NONHUMAN; OBSERVATIONAL STUDY; PEPTOCLOSTRIDIUM DIFFICILE; PRESCRIPTION; PRIORITY JOURNAL; CLOSTRIDIUM INFECTION; CROSS INFECTION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; ISOLATION AND PURIFICATION; MICROBIOLOGY; MULTILOCUS SEQUENCE TYPING; PROCEDURES; SUPPLY AND DISTRIBUTION; TRANSMISSION;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; ENGLAND; FLUOROQUINOLONES; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INCIDENCE; INFECTION CONTROL; MULTILOCUS SEQUENCE TYPING;

EID: 85011357089     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)30514-X     Document Type: Article

References (41)

1. 1 Davies, KA, Longshaw, CM, Davis, GL, et al. Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect Dis 14 (2014), 1208–1219.
2. 2 Lessa, FC, Mu, Y, Bamberg, WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 372 (2015), 825–834.
3. 3 Owens, RC Jr, Donskey, CJ, Gaynes, RP, Loo, VG, Muto, CA, Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 46 (2008), S19–S31.
4. 4 Shuttleworth, R, Taylor, M, Jones, DM, Antimicrobial susceptibilities of Clostridium difficile. J Clin Pathol 33 (1980), 1002–1005.
5. 5 Spigaglia, P, Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection. Ther Adv Infect Dis 3 (2016), 23–42.
6. 6 Johnson, S, Samore, MH, Farrow, KA, et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med 341 (1999), 1645–1651.
7. 7 Pear, SM, Williamson, TH, Bettin, KM, Gerding, DN, Galgiani, JN, Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann Intern Med 120 (1994), 272–277.
8. 8 Loo, VG, Poirier, L, Miller, MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353 (2005), 2442–2449.
9. 9 He, M, Miyajima, F, Roberts, P, et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet 45 (2013), 109–113.
10. 10 Kallen, AJ, Thompson, A, Ristaino, P, et al. Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection at a community hospital. Infect Control Hosp Epidemiol 30 (2009), 264–272.
11. 11 Muto, CA, Blank, MK, Marsh, JW, et al. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive “bundle” approach. Clin Infect Dis 45 (2007), 1266–1273.
12. 12 Eyre, DW, Cule, ML, Wilson, DJ, et al. Diverse sources of C. difficile infection identified on whole-genome sequencing. N Engl J Med 369 (2013), 1195–1205.
13. 13 Martin J, Eyre DW, Fawley WN, Walker AS, Crook DW, Wilcox MH. 2016 C. difficile (CD) ribotypes exhibit variable patient-to-patient transmission rates, as determined by whole-genome sequencing (WGS), suggesting differing reservoirs and modes of acquisition. ECCMID; Amsterdam; April 9–12, 2016. Abstract O557.
14. 14 Kumar, N, Miyajima, F, He, M, et al. Genome-based infection tracking reveals dynamics of Clostridium difficile transmission and disease recurrence. Clin Infect Dis 62 (2016), 746–752.
15. 15 Curry, SR, Muto, CA, Schlackman, JL, et al. Use of multilocus variable number of tandem repeats analysis genotyping to determine the role of asymptomatic carriers in Clostridium difficile transmission. Clin Infect Dis 57 (2013), 1094–1102.
16. 16 Wilcox, MH, Shetty, N, Fawley, WN, et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England. Clin Infect Dis 55 (2013), 1056–1063.
17. 17 Public Health England and the Department of Health. Clostridium difficile infection: How to deal with the problem. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1232006607827 (accessed Feb 16, 2016).
18. 18 Department of Health, NHS. Saving Lives: reducing infection, delivering clean and safe care, antimicrobial prescribing, a summary of best practice. http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_078117.pdf, 2007 (accessed Feb 16, 2016).
19. 19 Cornely, OA, Crook, DW, Esposito, R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 12 (2012), 281–289.
20. 20 Louie, TJ, Miller, MA, Mullane, KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364 (2011), 422–431.
21. 21 Jolley, KA, Maiden, MC, BIGSdb: scalable analysis of bacterial genome variation at the population level. BMC Bioinformatics, 11, 2010, 595.
22. 22 Drudy, D, Quinn, T, O'Mahony, R, Kyne, L, O'Gaora, P, Fanning, S, High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. J Antimicrob Chemother 58 (2006), 1264–1267.
23. 23 Spigaglia, P, Barbanti, F, Mastrantonio, P, et al. Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J Med Microbiol 57 (2008), 784–789.
24. 24 Didelot, X, Wilson, DJ, ClonalFrameML: efficient inference of recombination in whole bacterial genomes. PLoS Comput Biol, 11, 2015, e1004041.
25. 25 Isaac, NJB, Turvey, ST, Collen, B, Waterman, C, Baillie, JEM, Mammals on the EDGE: conservation priorities based on threat and phylogeny. PLoS One, 2, 2007, e296.
26. 26 Dingle, KE, Elliott, B, Robinson, E, et al. Evolutionary history of the Clostridium difficile pathogenicity locus. Genome Biol Evol 6 (2014), 36–52.
27. 27 Public Health England. Clostridium difficile Ribotyping Network (CDRN) for England and Northern Ireland, 2011–2013 Report. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/329156/C_difficile_ribotyping_network_CDRN_report.pdf (accessed Feb 1, 2016).
28. 28 Drudy, D, Fanning, S, Kyne, L, Toxin A-negative, toxin B-positive Clostridium difficile. Int J Infect Dis 11 (2007), 5–10.
29. 29 Borgmann, S, Kist, M, Jakobiak, T, et al. Increased number of Clostridium difficile infections and prevalence of Clostridium difficile PCR ribotype 001 in southern Germany. Euro Surveill, 13, 2008, 19057.
30. 30 Spigaglia, P, Barbanti, F, Dionisi, AM, Mastrantonio, P, Clostridium difficile isolates resistant to fluoroquinolones in Italy: emergence of PCR ribotype 018. J Clin Microbiol 48 (2010), 2892–2896.
31. 31 Eyre, DW, Griffiths, D, Vaughan, A, et al. Asymptomatic Clostridium difficile colonisation and onward transmission. PLoS One, 12, 2013, e78445.
32. 32 Bauer, MP, Kuijper, EJ, Potential sources of Clostridium difficile in human infection. Infect Dis Clin North Am 29 (2015), 29–35.
33. 33 Brown, KA, Khanafer, N, Daneman, N, Fisman, DM, Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother 57 (2013), 2326–2332.
34. 34 Talpaert, MJ, Rao, GG, Cooper, BS, Wade, P, Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infection. J Antimicrob Chemother 66 (2011), 2168–2174.
35. 35 Sarma, JB, Marshall, B, Cleeve, V, Tate, D, Oswald, T, Woolfrey, S, Effects of fluoroquinolone restriction (from 2007 to 2012) on Clostridium difficile infections: interrupted time-series analysis. J Hosp Infect 91 (2015), 74–80.
36. 36 Feazel, LM, Malhotra, A, Perencevich, EN, Kaboli, P, Diekema, DJ, Schweizer, ML, Effect of antibiotic stewardship programmes on Clostridium difficile incidence: a systematic review and meta-analysis. J Antimicrob Chemother 69 (2014), 1748–1754.
37. 37 Belmares, J, Johnson, S, Parada, JP, et al. Molecular epidemiology of Clostridium difficile over the course of 10 years in a tertiary care hospital. Clin Infect Dis 49 (2009), 1141–1147.
38. 38 Valiquette, L, Cossette, B, Garant, MP, Diab, H, Pépin, J, Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 45:suppl 2 (2007), S112–S121.
39. 39 Hensgens, MP, Goorhuis, A, van Kinschot, CM, Crobach, MJ, Harmanus, C, Kuijper, EJ, Clostridium difficile infection in an endemic setting in the Netherlands. Eur J Clin Microbiol Infect Dis 30 (2011), 587–593.
40. 40 Loo, VG, Bourgault, AM, Poirier, L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 365 (2011), 1693–1703.
41. 41 English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) 2010 to 2014, Report 2015. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/477962/ESPAUR_Report_2015.pdf (accessed Feb 16, 2016).